DOI：10.1038/nature14175 中国科研用户发表 作者：Frank van Aarle & Sauzanne Khalilieh
摘要 : Sauzanne Khalilieh 及同事报告了一项“概念证明”I-期临床试验，该试验显示：用“tildrakizumab”(与IL-23的p19亚单元相结合的一个抗体)来定向处理促炎性细胞因子“白介素-23” (IL-23)，会导致患中度到重度牛皮癣的患者疾病症状有所改善。
Sauzanne Khalilieh 及同事报告了一项“概念证明”I-期临床试验，该试验显示：用“tildrakizumab”(与IL-23的p19亚单元相结合的一个抗体)来定向处理促炎性细胞因子“白介素-23” (IL-23)，会导致患中度到重度牛皮癣的患者疾病症状有所改善。这种抗体耐受性很好，说明选择性地以IL-23为目标进行定向治疗值得进一步研究。
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2–3% of the population worldwide and has severe effects on patients’ physical and psychological well-being1, 2, 3. The discovery that psoriasis is an immune-mediated disease has led to more targeted, effective therapies; recent advances have focused on the interleukin (IL)-12/23p40 subunit shared by IL-12 and IL-23. Evidence suggests that specific inhibition of IL-23 would result in improvement in psoriasis. Here we evaluate tildrakizumab, a monoclonal antibody that targets the IL-23p19 subunit, in a three-part, randomized, placebo-controlled, sequential, rising multiple-dose phase I study in patients with moderate-to-severe psoriasis to provide clinical proof that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects. A 75% reduction in the psoriasis area and severity index (PASI) score (PASI75) was achieved by all subjects in parts 1 and 3 (pooled) in the 3 and 10 mg kg−1 groups by day 196. In part 2, 10 out of 15 subjects in the 3 mg kg−1 group and 13 out of 14 subjects in the 10 mg kg−1 group achieved a PASI75 by day 112. Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples.
来源： Nature 浏览次数：0